Natural history of multiple myeloma patients refractory to venetoclax: A single center experience

Am J Hematol. 2021 Mar 1;96(3):E68-E71. doi: 10.1002/ajh.26064. Epub 2020 Dec 28.

Affiliations

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.
² Department of Pharmaceutical Services, Winship Cancer Institute, Emory University Hospitals, Atlanta, Georgia, USA.

PMID: 33275813
DOI: 10.1002/ajh.26064

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Chromosomes, Human, Pair 11 / genetics
Chromosomes, Human, Pair 11 / ultrastructure
Chromosomes, Human, Pair 14 / genetics
Chromosomes, Human, Pair 14 / ultrastructure
Clinical Trials, Phase III as Topic / statistics & numerical data
Drug Resistance, Neoplasm*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Molecular Targeted Therapy*
Multiple Myeloma / drug therapy*
Multiple Myeloma / genetics
Multiple Myeloma / mortality
Patient Selection
Prognosis
Progression-Free Survival
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
Salvage Therapy*
Sulfonamides / administration & dosage
Sulfonamides / adverse effects
Sulfonamides / therapeutic use*
Translocation, Genetic

Substances

Bridged Bicyclo Compounds, Heterocyclic
Proto-Oncogene Proteins c-bcl-2
Sulfonamides
venetoclax